Johnson & Johnson announced positive topline results for overall survival from the phase III MARIPOSA study, evaluating Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions (ex19del) or L858R substitution mutations.Â
Elinzanetant successfully met the primary endpoints of the phase III trial OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in women with breast cancer or at high risk of developing breast cancer, demonstrating statistically significant reductions in the frequency of moderate to severe vasomotor symptoms (also known as hot flashes) from baseline to week four and 12 compared to placebo.Â
A new phase III trial led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that a diet low in omega-6 and high in omega-3 fatty acids, combined with fish oil supplements, significantly reduced the growth rate of prostate cancer cells in men with early-stage disease.
A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought.
Researchers from City of Hope, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, the University of Pennsylvania, and NIH have developed a way to add features to T cells to help them overcome mechanisms of chimeric antigen receptor T-cell therapy resistance. The new system is outlined in a paper published in Nature Biomedical Engineering.
Several physicians and lymphoma experts who work closely with the Lymphoma Research Foundation presented abstracts at the 66th annual ASH Annual Meeting and Exposition in San Diego, CA on Dec. 7-10, 2024.
One or two doses of psilocybin, a compound found in psychedelic mushrooms, may improve the mental health of cancer patients when accompanied by psychotherapy, a new report suggests. A second new study found that treatment with psilocybin resulted in lasting, positive personality changes in patients with alcohol use disorder.
A retrospective cohort study in women with breast cancer suggests that low oral doses of minoxidil taken during or after cancer treatment appear to regrow hair in most patients without causing any serious heart-related side effects that require additional therapies or hospitalization.
Patients can die if they take certain previously prescribed beta-blockers during a hematopoietic cell transplant due to suppressed signals from nerves that promote bone marrow regeneration, according to scientists at the Children’s Medical Center Research Institute at UT Southwestern, published in Cancer Discovery, builds upon previous CRI research by analyzing retrospective patient data to correlate beta-blocker use with significantly worse patient outcomes.
UT Southwestern Medical Center researchers identified a genetic mutation that slows the growth of melanoma and potentially other cancers by harnessing the power of the immune system.Â
